大黄蛰虫胶囊治疗子宫内膜异位症

Clinical Study on Dahuang Zhechong Capsule for Treating Endometriosis

目的:探讨大黄蛰虫胶囊治疗子宫内膜异位症的疗效及对前列腺素(PG)的影响。方法:67例患者随机分为对照组34例和观察组33例。对照组口服米非司酮,12.5 mg/次,1次/d;观察组口服大黄蛰虫胶囊,5粒/次,2次/d。疗程均为12周。观察VAS评分,改良的B&B多维量表及测定血浆中前列腺素PGs。结果:治疗后观察组VAS评分低于对照组(P<0.05);观察组B&B多维量表评分低于对照组(P<0.01);治疗后观察组F2a(PGF2a),前列腺素E2(PGE2)及血栓素B2(TXB2)水平低于对照组,6酮前列腺素F1a(6-keto-PGF1a)高于对照组(P<0.05,P<0.01)。结论:大黄蛰虫胶囊能改善子宫内膜异位症患者临床症状、体征;可能是通过调节PG水平发挥其缓解痛经等症状。

Objective： To explore the effect of Dahuang Zhechong capsule （DZC） for treating endometriosis and the influence to prostaglandin （PG）. Method： Sixty-seven cases of patients with endometriosis were randomly divided into control group and experimental group, while control group was received mifepristone （12.5 mg daily）, and experimental group received DZ, 5 tablets bid. The treatment was lasted for 12 weeks. Score of visual analogue scale （VAS） and the score of B＆B multidimensional scale were investigated, and the level of plasma PGs were determined. Result： VAS score in the experimental group was lower than that in the control group （P 〈 0.05）. B＆B multidimensional scale score in the experimental group was lower than that in the control group （P 〈0.01 ）. Level of prostaglandin F2o （PGF2a） , prostaglandin E~ （PGE~） and thromboxane B2 （TXB2） of experimental group was lower than those of control group （ P 〈 0.05 ）. But level of 6-keto-PGF1 a of experimental group was higher than that of control group （P 〈 0.01 ）. Conclusion： For treating patients with endometriosis, DZC can improve symptom and signs. The effect of alleviating dysmenorrhea is likely related to regulation of levels of PGs.